retatrutide weight loss drug vs Tirzepatide (2026): Differences in Loss, Metabol – Revolution Health & Wellness Retatrutide Weight Loss Treatment in

This robust growth reflects increasing prevalence of diabetes and obesity worldwide, driving the demand for innovative therapeutic options

The aging gut faces multiple challenges: Reduced bacterial diversity - fewer species means less metabolic flexibility Decreased butyrate producers - particularly Faecalibacterium prausnitzii and Roseburia species Slower transit time - affecting fermentation patterns Changes in digestive secretions - impacting bacterial growth conditions Medication effects - many common medications affect gut bacteria These changes create a cycle where reduced butyrate production may be linked with increased intestinal permeability, low-grade inflammation, and further microbiome changes

Hohdatsu, T., Nakamura, M., Ishizuka, Y., Yamada, H

2 animals were lesioned with 6-OHDA in the right Hemisphere

In the Phase 3 obesity cohort, 4 mg produced about 19% weight loss at 80 weeks, with dropout no higher than placebo